Article Text

Download PDFPDF
THUR 037 Identification of biofluid markers of TDP-43 pathology
  1. Shafei Rachelle1,
  2. Foiani Martha2,3,
  3. Heller Carolin2,3,
  4. Heslegrave Amanda2,3,
  5. Woollacott Ione1,
  6. Dick Katrina1,
  7. Warren Jason1,
  8. Schott Jonathan1,
  9. Zetterberg Henrik2,3,4,5,
  10. Rohrer Jonathan1
  1. 1Dementia Research Centre, Department of Neurodegenerative Disease
  2. 2Department of Molecular Neuroscience, UCL Institute of Neurology
  3. 3UK Dementia Research Institute, London
  4. 4Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
  5. 5Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology
  6. 6The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden


Introduction Frontotemporal dementia (FTD) is usually caused pathologically by either tau or TDP-43. Previous biofluid assays of TDP-43 have not so far proved to be sensitive or specific for identifying those cases with TDP-43 pathology.

Material and methods We set out to investigate the novel TDP-43 Simoa assay (Quanterix) assay in both plasma and CSF in a cohort of patients recruited from the University College London FTD observational studies with known or likely TDP-43 pathology (17), non-TDP-43 pathology (13), and healthy controls (10).

Results The mean [standard deviation] plasma TDP-43 concentration was higher in those with likely TDP-43 pathology (155.1 [223.4] pg/ml) than those with non-TDP pathology (112.39 [252.9] pg/ml), and healthy controls (50.0 [23.1] pg/ml), but the differences between groups was non-significant, with substantial overlap in concentrations between all three groups. The mean CSF TDP-43 concentration was 2.9 [0.3] pg/ml in those with likely TDP-43 pathology, 2.8 [0.4] pg/ml in those with non-TDP pathology, and 3.1 [0.5] pg/ml in healthy controls.

Discussion The assay tested in this study does not accurately distinguish between those with likely TDP-43 pathology and either disease controls or healthy individuals. There remains an urgent need to develop a better biofluid assay for pathological TDP-43.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.